June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...
Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Sprycel (dasatinib) is a prescription drug used to treat certain types of leukemia. Sprycel’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you ...
In adults with Philadelphia chromosome–positive ALL, the use of ABL-specific TK inhibitors, with or without systemic chemotherapy, allows most patients to have a complete hematologic response; a ...
PHYRAGO is a tyrosine kinase inhibitor indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), adult patients with Philadelphia ...
In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...
CHICAGO (Reuters) - Bristol-Myers' blood cancer drug Sprycel may work faster than Novartis' Gleevec, the once-a-day pill that transformed the treatment of some kinds of leukemia, researchers said on ...
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results